Signal Pharmaceuticals, Inc.

Celgene Corporation

Weiming Xu

Ellen Filvaroff

Kimberly Elizabeth Fultz

Shuichan Xu

Deborah Mortensen

Sabita Sankar

John J Sapienza

Lida R Tehrani

Patrick Papa

Rama Krishna Narla

Jan Elsner

Jennifer Riggs

Garrick Kenneth Packard

Jingjing Zhao

Sophie Perrin-Ninkovic

Jason Parnes

Roy Leonard Harris, Iii

Graziella I Shevlin

Branden Gingsee Lee

Loui Madakamutil

Tam Minh Tran

Rajesh Chopra

Roy L Harris, Iii

Yuhong Ning

Laura G Corral

Branden Lee

Torsten Trowe

Graziella Shevlin

Fultz Kimberly

Madakamutil Loui

Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.

Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines

Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer, wherein the TOR kinase inhibitor is a compound of formula (I): 

Provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by a LKB1 and/or AMPK gene or protein loss or mutation.

Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors

Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3&#x3b2; or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3&#x3b2; or p70S6K1.

Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity

Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity

Provided herein are Heteroaryl Compounds having the following structure: 

Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway

Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway

Methods of treating, preventing and/or managing an immunodeficiency disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent. Methods of boosting humoral immunity are also disclosed.

Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders

Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway

Growing community of inventors

San Diego, CA, United States of America

Weiming Xu